Your session is about to expire
← Back to Search
Pembrolizumab for Diffuse Large B-Cell Lymphoma (SPiReL Trial)
SPiReL Trial Summary
This trial is testing a new cancer treatment that consists of two priming doses of a 0.5 mL injection of DPX-Survivac, given 21 days apart, followed by up to six maintenance injections of 0.1 mL every two months for one year. The injections will be given with low-dose metronomic oral cyclophosphamide (50 mg twice daily) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.
- Adult Refractory Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Recurrence
SPiReL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSPiReL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SPiReL Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research endeavor currently looking for participants?
"As stated on clinicaltrials.gov, this medical trial is no longer actively seeking candidates as the last update was made November 9th 2022. Despite that there are still 3515 other trials open to patient recruitment at present. This particular study originally posted on March 13th of 2018."
What is the current size of the cohort participating in this clinical trial?
"This study has ceased to accept participants for the time being. It was first posted on March 13th 2018, and its most recent edit occured November 9th 2022. Those seeking alternative clinical trials may find success with 1769 active studies involving recurrent illness or 1746 studies related to DPX-Survivac recruitment."
Is there a precedent for investigating the effects of DPX-Survivac?
"Since its introduction in the late 1990s, DPX-Survivac has been subject to 1326 completed clinical trials. Currently, 1746 trials are actively recruiting patients; many of these studies centered around Halifax."
What is the breadth of this trial's scope across various medical sites?
"This clinical trial is currently running at seven locations, including the Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre in Halifax,Tom Baker Cancer Centre - Alberta Health Services in Calgary and Sunnybrook Health Sciences Centre, Odette Cancer Centre in Toronto. The remaining 4 sites are also included here."
To what end is DPX-Survivac typically utilized?
"DPX-Survivac is frequently utilized to battle malignant melanoma of the skin. Furthermore, it may prove helpful in cases such as recurrent cervical cancer, leukemia and refractory or relapsed mediastinal large b-cell lymphoma."
Has DPX-Survivac received regulatory approval from the FDA?
"Due to the lack of efficacy data, DPX-Survivac's safety rating is 2 based on Power's metric. This phase 2 trial has provided some evidence supporting its relative safety but not much in terms of effectiveness."
Share this study with friends
Copy Link
Messenger